Most Common Side Effects of Lupron (Leuprolide Acetate)
The most common side effects of Lupron are hot flashes (occurring in 45-59% of patients), injection site reactions, and symptoms related to sex hormone suppression including decreased libido, erectile dysfunction, weight gain, and mood changes. 1
Primary Side Effects by Category
Vasomotor Symptoms
- Hot flashes are the most frequently reported adverse effect, occurring in 45% of adult patients with prostate cancer and up to 59% in clinical trials 2, 3
- These result from the suppression of sex hormones and are nearly universal in patients receiving leuprolide 4
Injection Site Reactions
- Injection site pain and reactions are common, particularly with depot formulations 1
- Injection site swelling occurs in >2% of patients receiving the 3-month formulation 1
- Rare cases of injection site abscess have been reported 1
Psychiatric and Neurological Effects
- Emotional lability (including crying, irritability, impatience, anger, and aggression) is common, particularly in pediatric patients receiving LUPRON DEPOT-PED 1
- Headache occurs in ≥2% of patients across all formulations 1
- Mood alterations are reported in >2% of patients on the 3-month formulation 1
- Convulsions have been observed, particularly in patients with pre-existing seizure disorders or CNS abnormalities 1
Sexual and Reproductive Effects
- Loss of libido and erectile dysfunction occur in the majority of male patients due to testosterone suppression 4
- Testicular atrophy occurs in 21% of patients 3
- In females, vaginal bleeding/discharge and vaginitis occur in ≥2% of patients 1
- Breast tenderness is reported in ≥4% of patients on the 6-month formulation 1
Metabolic and Physical Changes
- Weight gain occurs in >2% of patients, with some experiencing increases >3 kg 1, 4
- Decreased hemoglobin (mean decrease of 0.8 gm/100 mL) has been documented 4
- Testicular volume decrease of approximately 28.9% occurs in male patients 4
Gastrointestinal Effects
- Abdominal pain, nausea, and diarrhea occur in ≥4% of patients on the 6-month formulation 1
- General pain occurs in ≥2% of patients 1
Dermatologic Effects
- Acne/seborrhea occurs in ≥2% of patients 1
- Rash (including erythema multiforme) occurs in ≥2-4% of patients 1
- Pruritus and hyperhidrosis occur in ≥4% of patients on the 6-month formulation 1
Musculoskeletal Effects
- Back pain occurs in 16-27% of patients and is ≥4% with the 6-month formulation 1, 2
- Arthralgia occurs in 14% of patients 2
- Pain in extremity occurs in ≥4% of patients 1
Pediatric-Specific Considerations
- In children with central precocious puberty, initial worsening of pubertal signs may occur during the first weeks of therapy due to the initial stimulatory effect before suppression 1
- Pseudotumor cerebri (idiopathic intracranial hypertension) has been reported in pediatric patients, presenting with headache, papilledema, and blurred vision 1
Important Clinical Context
Tolerability Profile
- Despite the high frequency of side effects (95% of patients experience some hypoestrogenic effects in fibroid studies), only 8% of patients terminated treatment prematurely 5
- In routine clinical practice, adverse events occurred in only 9% of patients, with the majority being non-serious 6
- Treatment-related serious adverse events are generally low (0.6-11.7%) across age groups 7